Загрузка...
Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients
The aim of this study was to evaluate the impact of white blood cell (WBC) counts at presentation on the achievement of deep molecular response. A total of 362 newly diagnosed chronic-phase chronic myeloid leukemia patients (CML-CP) receiving 400 mg/day imatinib were serially monitored for a median...
Сохранить в:
| Опубликовано в: : | Medicine (Baltimore) |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer Health
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4718283/ https://ncbi.nlm.nih.gov/pubmed/26765457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002486 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|